Longitudinal MRI study of the pituitary volume in chronic schizophrenia: A preliminary report

Psychiatry Research - Neuroimaging

Volumn 202, Issue 1, 2012, Pages 84-87

  Takahashi, Tsutomu ^a,b   Kido, Mikio ^a   Nakamura, Kazue ^a   Furuichi, Atsushi ^a   Zhou, Shi Yu ^c   Kawasaki, Yasuhiro ^a,d   Noguchi, Kyo ^a   Seto, Hikaru ^a   Kurachi, Masayoshi ^a   Suzuki, Michio ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Magnetic resonance imaging; Pituitary gland; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HYPOPHYSIS; HYPOPHYSIS DISEASE; LONGITUDINAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PITUITARY ATROPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ATROPHY; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; PITUITARY GLAND; SCHIZOPHRENIA;

EID: 84862529825     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.11.008     Document Type: Article

References (18)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms/Scale for the Assessment of Positive Symptoms [Manual] 1984, University of Iowa Press, Iowa City.
2. Cohrs S., Röher C., Jordan W., Meier A., Huether G., Wuttke W., Rüther E., Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 2006, 185:11-18.
3. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., Brewer W.J., Smith D.J., Dazzan P., Berger G.E., Yung A.R., van den Buuse M., Murray R., McGorry P.D., Pantelis C. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry 2005, 58:417-423.
4. Klomp A., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S., Van Haren N.E. Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. International Journal of Neuropsychopharmacology 2012, 15:281-288.
5. MacMaster F.P., El-Sheikh R., Upadhyaya A.R., Nutche J., Rosenberg D.R., Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study. Schizophrenia Research 2007, 92:207-210.
6. Nicolo J.P., Berger G.E., Garner B.A., Velakoulis D., Markulev C., Kerr M., McGorry P.D., Proffitt T.M., McConchie M., Pantelis C., Wood S.J. The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study. Schizophrenia Research 2010, 116:49-54.
7. Pariante C.M. Pituitary volume in psychosis: the first review of the evidence. Journal of Psychopharmacology 2008, 22:76-81.
8. Pariante C.M., Vassilopoulou K., Velakoulis D., Phillips L., Soulsby B., Wood S.J., Brewer W., Smith D.J., Dazzan P., Yung A.R., Zervas I.M., Christodoulou G.N., Murray R., McGorry P.D., Pantelis C. Pituitary volume in psychosis. The British Journal of Psychiatry 2004, 185:5-10.
9. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., Fearon P., Orr K., Hutchinson G., Pantelis C., Velakoulis D., Jones P.B., Leff J., Murray R.M. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005, 30:1923-1931.
10. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., Berger G. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. The Australian and New Zealand Journal of Psychiatry 2006, 40:725-741.
11. Sassi R.B., Nicoletti M., Brambilla P., Harenski K., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Decreased pituitary volume in patients with bipolar disorder. Biological Psychiatry 2001, 50:271-280.
12. Scheepers F.E., Gespen de Wied C.C., Kahn R.S. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. Journal of Clinical Psychopharmacology 2001, 21:575-582.
13. Takahashi T., Suzuki M., Velakoulis D., Lorenzetti V., Soulsby B., Zhou S.Y., Nakamura K., Seto H., Kurachi M., Pantelis C. Increased pituitary volume in schizophrenia spectrum disorders. Schizophrenia Research 2009, 108:114-121.
14. Takahashi T., Zhou S.Y., Nakamura K., Tanino R., Furuichi A., Kido M., Kawasaki Y., Noguchi K., Seto H., Kurachi M., Suzuki M. Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and first-episode schizophrenia. Proggress in Neuropsychopharmacology and Biological Psychiatry 2011, 35:177-183.
15. Tournikioti K., Tansella M., Perlini C., Rambaldelli G., Cerini R., Versace A., Andreone N., Dusi N., Balestrieri M., Malagò R., Gasparini A., Brambilla P. Normal pituitary volumes in chronic schizophrenia. Psychiatry Research: Neuroimaging 2007, 154:41-48.
16. Upadhyaya A.R., El-Sheikh R., MacMaster F.P., Diwadkar V.A., Keshavan M.S. Pituitary volume in neuroleptic-naïve schizophrenia: a structural MRI study. Schizophrenia Research 2007, 90:266-273.
17. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annual Review of Clinical Psychology 2008, 4:189-216.
18. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993, WHO, Geneva.